Ex-vivo-Ansprechen auf die Behandlung von Primärtumoren und / oder assoziierten Metastasen für die präklinische und klinische Entwicklung von Therapeutika

Overview

This study presents an ex vivo drug response technique aimed at enhancing drug development in cancer research. By analyzing primary tumor specimens, the method evaluates therapeutic responses and molecular mechanisms of resistance.

Key Study Components

Area of Science

• Cancer Research
• Drug Development
• Ex Vivo Analysis

Background

• Established cancer cell lines have limitations in predicting therapeutic responses.
• The tumor microenvironment significantly influences drug efficacy.
• Ex vivo techniques can provide more relevant insights into drug responses.
• This study focuses on primary tumor specimens for better drug development.

Purpose of Study

• To implement an ex vivo analysis for drug response evaluation.
• To inform on drug efficacy and off-target effects.
• To analyze molecular resistance mechanisms in tumors.

Methods Used

• Procurement of viable tumor specimens for analysis.
• Embedding and sectioning of tissue samples.
• Treatment with drugs at therapeutically relevant doses.
• Evaluation of morphological changes to assess drug response.

Main Results

• Drug treatment led to observable morphological changes indicative of apoptosis.
• IC 50 values were determined for drug responses.
• Off-target effects were identified through molecular analysis.
• Resistance and feedback mechanisms were evaluated in non-responsive tumor outgrowth.

Conclusions

• The ex vivo technique provides valuable insights into drug efficacy.
• Understanding the tumor microenvironment is crucial for drug development.
• This approach may enhance the predictive power of preclinical studies.

Frequently Asked Questions